Company MaaT Pharma

Equities

MAAT

FR0012634822

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for MaaT Pharma

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 08:05:14 2024-04-26 am EDT			5-day change	1st Jan Change
9.06 ^EUR	0.00%		+1.34%	+29.80%

Apr. 15	MaaT Pharma: positive data in graft-versus-host disease	CF
Apr. 15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.

The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).

Number of employees: 56

EUR in Million	2022	Weight	2023	Weight	Delta
Microbiome Ecosystem Therapies 100.0 %	1	100.0 %	2	100.0 %	+55.80%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	1	100.0 %	2	100.0 %	+55.80%

Managers	Title	Age	Since
Hervé Affagard FOU	Founder	-	13-12-31
Siân Crouzet DFI	Director of Finance/CFO	-	15-12-31
Emilie Plantamura CTO	Chief Tech/Sci/R&D Officer	-	22-02-28
Philippe Moyen COO	Chief Operating Officer	-	23-06-20
Carole Schwintner CTO	Chief Tech/Sci/R&D Officer	-	13-12-31
Nathalie Corvaïa CTO	Chief Tech/Sci/R&D Officer	-	22-10-03
Gervais Tougas CTO	Chief Tech/Sci/R&D Officer	67	23-06-20
Karine Gaudin ADM	Chief Administrative Officer	58	21-12-31
Guilhaume Debroas IRC	Investor Relations Contact	-	23-06-20

Members of the board	Title	Age	Since
Isabelle de Cremoux BRD	Director/Board Member	54	13-12-31
Claude Bertrand BRD	Director/Board Member	61	20-07-15
Muriel Prudent BRD	Director/Board Member	-	-
Jean-Marie Lefèvre BRD	Director/Board Member	-	15-12-31
Hervé Affagard FOU	Founder	-	13-12-31
Karim Dabbagh CHM	Chairman	-	23-06-20
Jean Volatier BRD	Director/Board Member	59	21-10-13
Dorothée Burkel BRD	Director/Board Member	61	21-10-13
Nadia Kamal BRD	Director/Board Member	-	23-06-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,616,306	6,444,310 ( 55.48 %)	0	55.48 %

Name	Equities	%	Valuation
Seventure Partners SA 22.32 %	2,593,068	22.32 %	25 M €
Symbiosis LLC /DC/ 17.46 %	2,027,702	17.46 %	19 M €
BPIFrance Investissement SAS 15.52 %	1,802,439	15.52 %	17 M €
Crédit Mutuel Impact SA 12.16 %	1,412,364	12.16 %	13 M €
Pharcor SAS 10.57 %	1,227,905	10.57 %	12 M €
Hervé Affagard 1.714 %	199,159	1.714 %	2 M €
Financière Arbevel SA 0.1722 %	20,000	0.1722 %	190 080 €
Gestys SA 0.0129 %	1,500	0.0129 %	14 256 €

Maat Pharma SA

70, Avenue Tony Garnier

69007, Lyon

+33 4 28 29 14 00

http://www.maatpharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.06 EUR

Average target price

15.5 EUR

Spread / Average Target

+71.08%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MAAT PHARMA	+29.80%	113M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs